A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma

Human Gene Therapy

Volumn 10, Issue 10, 1999, Pages 1721-1733

  Hallenbeck, Paul L ^a   Chang, Yung Nien ^a   Hay, Carl ^a   Golightly, Douglas ^a   Stewart, David ^a   Lin, Jane ^a   Phipps, Sandrina ^a   Chiang, Yawen L ^a,b  

^a Novartis Company   (United States)

^b RPR Gencell   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; VIRUS VECTOR;

ARTICLE; CANCER MORTALITY; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LUNG ALVEOLUS EPITHELIUM; LUNG ENDOTHELIUM; SURVIVAL RATE; TUMOR GROWTH;

ADENOVIRUSES, HUMAN; ALPHA-FETOPROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; GENE THERAPY; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MICE; NEOPLASMS, EXPERIMENTAL; PROMOTER REGIONS (GENETICS); TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0033166096     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017725     Document Type: Article

References (34)

1. ADEN, D.P., FOGEL, A., PLOTKIN, S., DAMJANOV, I., and KNOWLES, B. (1979). Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature (London) 282, 615-616.
2. BISCHOFF, J.R., KIRN, D.H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., NG, L., NYE, I.A., SAMPSON-JOHANNES, A., FARRAEY, A., and MCCORMICK, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
3. CAMPER, S.A., and TILGHMAN, S.M. (1991). The activation and silencing of gene transcription in the liver. Biotechnology 16, 81-87.
4. CHANG, S. (1954). Continuous subcultivation of epithelial-like cells from normal human tissues. Proc. Soc. Exp. Biol. Med. 87, 440-443.
5. CHEN, C., CHANG, Y., RYAN, P., LINSCOTT, M. McGARRITY, G., and CHIANG, Y.L. (1995). Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect". Hum. Gene Ther. 6, 1467-1476.
6. CULVER, K.W., RAM, Z., WALBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producing cells for treatment of experimental brain tumors. Science 256, 1550-1552.
7. DOI, I. (1975). Establishment and some biological characteristics of human hepatoma cell lines. Jpn. J. Cancer Res. 66, 385-392.
8. GOLDSMITH, K.T., DION, L.D., CURIEL, D.T., and GARVER, R.I. (1998). Trans E1 component requirements for maximal replication of E1-defective recombinant adenovirus. Virology 248, 406-419.
9. GORZIGLIA, M.I., KADAN, M.J., YEI, S., LIN, J., LEE, G.M., LUTHRA, R., and TRAPNELL, B.C. (1996). Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70, 4173-4178.
10. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NARIN, R. (1977). Characteristics of a human cell transformed by DNA human adenovirus type 5. J. Gen. Virol. 36, 59-72.
11. GUERETTE, B., VILQUIN, J.T., GINGRAS, M., GRAVEL, C., WOOD, K.J., and TREMBLAY, J.P. (1996). Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum. Gene Ther. 7, 1455-1463.
12. HAYNER, N.T., BRAUN, L., YASWEN, P., BROOKS, M., and FAUSTO, N. (1984). Isozyme profiles of oval cells, parenchymal cells, and biliary cells isolated by centrifugal elutriation from normal and preneoplastic livers. Cancer Res. 44, 332-338.
13. HITT, M.H., and GRAHAM, F.L. (1990). Adenovirus E1a under the control of heterologous promoters: Wide variation in E1a expression levels has little effect on virus replication. Virology 179, 667-677.
14. HOLDER, J.W., ELMORE, E., and BARRETT, J.C. (1993). Gap junction function and cancer. Cancer Res. 53, 3475-3485.
15. HORWITZ, M.S., FIELDS. B.N., and KNIPE, D.M. (1990). Adenoviridae and their replication. In Virology. (Raven Press. New York) pp. 1679-1721.
16. HUBER, B.E., RICHARDS, C.A., and KRENITSKY, T.A. (1991). Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach to cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 88, 8039-8043.
17. KANEKO, S., HALLENBECK, P., KOTANI, T., NAKABAYASHI, H., McGARRITY, G., TAMAOKI, T., ANDERSON, W.F., and CHIANG, Y.L. (1995). Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 55, 5283-5287.
18. KAST, W.M., OFFRINGA, R., PETERS, P.J., VOORDOUW, A.C., MELOEN, R.H., VAN DER EB, A.J., and MELIEF, C.J.M. (1989). Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59, 603-614.
19. LOCHMULLER, H., JANI, A., HUARD, J., PRESCOTT, S., SIMONEAU, M., MASSIE, B., KARPATI, G., and ACSADI, G. (1994). Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (deleted E1 + deleted E3) during multiple passages in 293 cells. Hum. Gene Ther. 5, 1485-1491.
20. LOK, A.S.F., and LAI, C.L. (1989). Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B infection: Role in early detection of hepatocellular carcinoma. Hepatology 9, 110-115.
21. NAKABAYASHI, H., TAKETA, K., YAMANE, T., MIYAZAKI, M., MAYANA, K., and SATO, J. (1984). Phenotypic stability of a human hepatoma cell line HuH-7, in long term culture with chemically defined medium. Jpn. J. Cancer Res. 75, 151-158.
22. NAKABAYASHI, H., HASHIMOTO, Y., MIYAO, Y., TJONG, K., CHAN, J., and TAMAOKI, T. (1991). A position-dependent silencer plays a major role in repressing α-fetoprotein expression in human hepatoma. Mol. Cell. Biol. 11, 5885-5893.
23. OLDFIELD, E.H., RAM, Z., CULVER, K.W., BLAESE, R.M., DEVROOM, H.L., and ANDERSON, W.F. (1993). Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene transferred by retroviral vectors. Hum. Gene Ther. 4, 39-69.
24. O'MALLEY, B.W., JR., CHEN, S., SCHWARTZ, M.R., and WOO, S.L.C. (1995). Adenovirus-mediated gene therapy for head and neck squamous cell cancer in a nude mouse model. Cancer Res. 55, 1080-1085.
25. O'REILLY, D., MILLER, L.K., LUCKOW, V., O'REILLY, D., MILLER, L.K., and LUCKOW, V. (1994). Baculoviral Expression Vectors. (Oxford University Press, New York) pp. 127-134.
26. REED, L.J., and MUENCH, H. (1938). A simple method for estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497.
27. RODRIGUEZ, R., SCHUUR, E.R., LIM, H.Y., HENDERSON, G.A., SIMONS, J.W., and HENDERSON, D.R. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559-2563.
28. SHENK, T., and FLINT, J. (1991). Transcriptional and transforming activities of the adenovirus E1a proteins. Adv. Cancer Res. 57, 47-84.
29. SHENK, T., JONES, N., COLBY, W., and FOWLKES, D. (1980). Functional analysis of adenovirus-5 host-range deletion mutants defective for transformation of rat embryo cells. Cold Spring Harbor Symp. Quant. Biol. 44 (Pt. 1), 367-375.
30. SMIT, T.A.G., WHITE, B.D., GARDNER, J.M., KALEKO, M., and McCLELLAND, A. (1996). Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther. 3, 496-502.
31. SPERGEL, J.M., and CHEN-KIANG, S. (1991). Interleukin 6 enhances a cellular activity that functionally substitutes for E1a protein in transactivation. Proc. Natl. Acad. Sci. U.S.A. 88, 6472-6476.
32. STEVENSON, F.K. (1991). Tumor vaccines. FASEB J. 5, 2250.
33. TAMAOKI, T., FAUSTO, N., STEIN, G.S., and STEIN, J.I. (1984). Expression of the α-fetoprotein gene during development, regeneration and carcinogenesis. In Recombinant DNA and Cell Proliferation. (Academic Press, Orlando, FL) pp. 145-168.
34. WILLS, K.N., HUANG, W., HARRIS, M.P., MACHEMER, T., MANEVAL, D.C., and GREGORY, R.J. (1995). Gene therapy for hepatocellular carcinoma: Chemosensitivity conferred by adenovirus-mediated transferred of the HSF-tk thymidine kinase gene. Cancer Gene Ther. 2, 191-197.